#United States Neurological Biomarkers Market forecast

[aarunresearcher]

United States neurological biomarkers market size is projected to exhibit a growth rate (CAGR) of 4.20% during 2024-2032. The elevating adoption of minimally invasive procedures and the growing number of clinical trials represent some of the key factors driving the market.

[health-views-updates]

2024 Biotechnology Reagents & Kits Market Analysis: Opportunities and Challenges

The global biotechnology reagents and kits market has entered an era of remarkable growth, with its market size valued at an estimated USD 660.67 billion in 2023. According to recent projections, the market is expected to surge to a staggering USD 1690.01 billion by 2032, driven by a compound annual growth rate (CAGR) of 11% over the forecast period from 2024 to 2032. This unprecedented expansion is being fueled by key factors including technological advancements, an increase in research activities, and the rising demand for innovative therapies across the biotechnology and pharmaceutical sectors.

Industry Dynamics and Key Drivers

The biotechnology reagents and kits market is a crucial component of the biotech and life sciences industries, comprising products that facilitate biological research, drug development, and diagnostic testing. The escalating demand for advanced biotechnological tools and reagents is propelling market growth, as these products are essential in various applications such as DNA sequencing, polymerase chain reaction (PCR), gene expression, and protein analysis.

Technological innovations in the biotechnology sector, particularly in the fields of genomics, proteomics, and cell biology, are significantly contributing to the expansion of the reagents and kits market. The emergence of CRISPR-Cas9 technology for genome editing, for instance, has created an unprecedented demand for reagents designed specifically for gene manipulation and molecular biology experiments.

The increasing prevalence of chronic diseases and the rising need for personalized medicine are also major drivers of growth. Biopharmaceutical companies and research institutions are constantly investing in the development of targeted therapies, which require precise and reliable reagents for drug testing and efficacy analysis. The biotechnology industry’s focus on developing novel treatments for diseases such as cancer, diabetes, and neurological disorders is further accelerating the demand for specialized kits and reagents.

Get a Free Sample Report@ https://www.snsinsider.com/sample-request/3954 

Market Segmentation and Applications

The biotechnology reagents and kits market can be segmented based on product type, application, end-user, and region. The major product categories include cell culture reagents, molecular biology reagents, immunoassay reagents, and others. Each product type is tailored for specific applications, ranging from basic research to clinical diagnostics.

In terms of application, drug discovery, diagnostics, and biopharmaceutical production represent the largest segments. Drug discovery, in particular, is anticipated to drive significant market growth, as pharmaceutical companies increasingly rely on high-quality reagents for screening potential drug candidates and conducting preclinical trials. The diagnostics segment is also experiencing rapid expansion, especially with the advent of molecular diagnostics, which rely on sophisticated reagents for detecting genetic mutations, pathogens, and biomarkers associated with various diseases.

End-users of biotechnology reagents and kits include academic and research institutions, biopharmaceutical companies, clinical laboratories, and hospitals. Biopharmaceutical companies are expected to dominate the market, as they continuously invest in cutting-edge biotechnologies to develop next-generation therapies. Meanwhile, the academic and research sector will see steady growth, supported by government funding and collaborative research efforts in the fields of molecular biology, genetics, and synthetic biology.

Regional Insights

Geographically, the biotechnology reagents and kits market is witnessing robust growth across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America, particularly the United States, currently holds the largest market share, driven by a strong presence of biotechnology and pharmaceutical companies, well-established research institutions, and significant government investment in life sciences.

Europe follows closely, with countries like Germany, the UK, and France contributing to market expansion through innovative research and development activities. The European Union’s focus on promoting biotechnology as a key driver of its healthcare and industrial strategies has further fueled demand for reagents and kits.

The Asia-Pacific region is expected to witness the highest growth rate over the forecast period, with countries such as China, India, and Japan leading the charge. Factors contributing to this growth include the rising prevalence of chronic diseases, increasing healthcare expenditure, and the growing number of biotechnology firms across the region. China’s burgeoning biopharmaceutical industry and India’s expanding contract research organization (CRO) sector are particularly noteworthy drivers of market growth in Asia-Pacific.

Challenges and Opportunities

While the biotechnology reagents and kits market presents significant growth opportunities, it also faces several challenges. Regulatory hurdles, high production costs, and stringent quality standards are some of the key factors that could potentially hinder market growth. Additionally, the complexity of biotechnology products and the need for skilled professionals to handle and analyze biological data pose challenges to market players.

Despite these challenges, the market offers tremendous potential for innovation. The increasing adoption of artificial intelligence (AI) and automation in biotechnology research is expected to streamline processes and improve the efficiency of reagent and kit production. Companies that invest in sustainable biotechnological solutions and focus on reducing environmental impact stand to gain a competitive advantage in the evolving landscape.

Conclusion

The biotechnology reagents and kits market is poised for unprecedented growth over the next decade. With the increasing demand for cutting-edge biotechnological solutions, advancements in genetic engineering, and rising healthcare needs, the market is set to reach USD 1690.01 billion by 2032, expanding at a CAGR of 11%. Companies that focus on innovation, regulatory compliance, and sustainability will be well-positioned to capitalize on the immense opportunities this burgeoning market offers.

[poonamcmi]

Neurodiagnostics Market Estimated to Witness High Growth Owing to Growing Geriatric Population

​The neurodiagnostics market plays a crucial role in neurological disease diagnosis and treatment monitoring. Neurological disorders such as epilepsy, Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, and other neurological conditions are becoming increasingly prevalent. Neurodiagnostics help detect neurological abnormalities through neurological imaging such as MRI, EEG, and diagnostic tests. The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics.

The Global Neurodiagnostics Market is estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.

Key Takeaways Key players operating in the neurodiagnostics are Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System.

The Neurodiagnostics Market Trends  include increasing investments in R&D for biomarker-based disease diagnosis and neuroimaging. The global expansion of key players through mergers and acquisitions will further aid market growth.

The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics. Furthermore, increasing investments in R&D by key players for developing advanced diagnostic systems will boost the neurodiagnostics market over the forecast period.

Market drivers The growing geriatric population is the major driver propelling the Neurodiagnostics Market Size And Trends As per the United Nations, people aged over 60 years are projected to outnumber children under 10 years by 2050. Elderly people are more vulnerable to neurological disorders like Alzheimer's and Parkinson's disease. This will augment the demand for neurodiagnostics for early disease diagnosis and treatment monitoring. Increasing awareness about brain health and availability of reimbursement policies for neurodiagnostic tests will also boost market revenues significantly over the forecast period.

PEST Analysis Political: Regulations related to medical devices and neurological disorder treatments have an impact. Reimbursement policies by governments and insurance agencies also affect market growth. Economic: The growing insurance coverage levels and disposable incomes have boosted healthcare spending including on neurodiagnostics. Higher investments in clinical trials and R&D remain crucial. Social: Rising prevalence of neurological disorders like Alzheimers, Parkinsons, epilepsy, and stroke is a key driver. Growing awareness encourages early diagnosis through imaging techniques. Technological: Advancements in imaging modalities like MRI, CT, PET, EEG, and newer technologies like digital EEG and MEG expands diagnosis capabilities. Portable and wearable devices improve accessibility.

Geographical Regions with High Market Concentration North America accounts for the largest share in the neurodiagnostics market in terms of value, owing to the presence of major players, high healthcare expenditure, and rising neurological disorders. The United States holds a significant share in the regional market.

Fastest Growing Regional Market The Asia Pacific region is expected to witness the highest growth in the neurodiagnostics market during the forecast period. This is attributed to factors such as growing healthcare expenditure, increasing healthcare infrastructure development, and rising geriatric population in the region suffering from neurological conditions. Rapidly developing countries like China and India with huge patient pools offer high growth potential. Get More Insights On, Neurodiagnostics Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[snehahealthcareblogs]

Digital Biomarkers Market : To Exhibits Remarkable Growth | $14.7 Billions by 2032

Digital biomarkers market was a rapidly emerging and evolving sector within healthcare and life sciences. Digital biomarkers are quantifiable and objective physiological and behavioral data collected and measured through the use of digital devices and technologies. These data can provide valuable insights into an individual's health status and can be used for various purposes, including disease diagnosis, monitoring, and treatment optimization.

Request Sample Report: https://www.alliedmarketresearch.com/request-sample/132906

Here are some key points about the digital biomarkers market:

Growing Importance: The digital biomarkers market was gaining importance due to advancements in wearable technology, mobile health apps, and remote monitoring tools. These technologies allowed for the continuous collection of health-related data, enabling healthcare providers to monitor patients more effectively.

Applications: Digital biomarkers found applications in various healthcare domains, including cardiology, neurology, psychiatry, and oncology. For example, in cardiology, wearable devices could track heart rate, activity levels, and sleep patterns to assess cardiac health.

Clinical Trials: Pharmaceutical companies were increasingly using digital biomarkers in clinical trials to collect real-world data on the efficacy and safety of drugs. Digital biomarkers helped streamline the drug development process and reduce costs.

Data Privacy and Security: The collection and use of personal health data through digital biomarkers raised concerns about data privacy and security. Regulations such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States and the General Data Protection Regulation (GDPR) in Europe played a crucial role in addressing these concerns.

Market Players: Several technology companies, healthcare organizations, and startups were entering the digital biomarkers market. This included companies producing wearable devices, developing health apps, and creating data analytics platforms to make sense of the collected data.

Challenges: Challenges in the digital biomarkers market included standardization of data collection and analysis methods, regulatory hurdles, and the need for interoperability among various devices and systems.

By application, the digital biomarkers market size is classified into cardiovascular disease, sleep and movement disease, neurological disorders, and others (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). The cardiovascular disease segment is projected to be the fastest growing segment during the forecast period owing to rise in prevalence of cardiovascular diseases and high in number of product provision of digital biomarkers for cardiovascular disease monitoring and diagnosis.

By clinical practice, the digital biomarkers market share is classified into monitoring, diagnostic and prognostic. The monitoring segment is projected to be the fastest growing segment during the forecast period owing to rise in adoption of digital biomarkers for monitoring purpose and hogh presence of manufacturers who manufactures digital biomarkers for monitoring.

By end user, the digital biomarkers market analysis is classified into healthcare companies, hospitals, and others (payers and patients). The healthcare companies segment is projected to be the fastest growing segment during the forecast period owing to rise in number of clinical trials and research activities using digital biomarkers by healthcare companies.

[reportsneww]

Neurological Biomarkers Market is anticipated to exhibit a CAGR of 11.9% from 2022 to 2030

Newark, New Castle, USA – Growth Plus Reports’ most recent study examines the Global Neurological Biomarkers Market’s production, prospective uses, demand, key companies, and SWOT analysis.

You may get insights into the TOC, and Statistics for essential facts, information, trends, and competitive landscape information.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/neurological-biomarkers-market/8040

The following are the leading companies in the Global Neurological Biomarkers market:

Abbott Laboratories Inc.

Quanterix Corporation

Thermo Fisher Scientific Inc.

Qiagen NV

Bio-Rad Laboratories Inc.

Merck KGaA

Banyan Biomarkers Inc.

Johnson & Johnson

ACOBIOM

Myriad Genetics Inc.

DiaGenic ASA

Olink Biosciences

Growth Plus Reports studies the key trends in each category and sub-segment of the Neurological Biomarkers market, along with Global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

SEGMENTATION

GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY TYPE

Genomic

Metabolomic

Proteomic

Imaging

Others

GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY APPLICATION

Alzheimer’s Disease

Parkinson’s Disease

Multiple Sclerosis

Others

GLOBAL NEUROLOGICAL BIOMARKERS MARKET – ANALYSIS & FORECAST, BY END-USER

Hospitals & Laboratories 

Independent Diagnostic Centers 

Research Organizations 

Others

For More Information or Query or Customization visit: https://www.growthplusreports.com/inquiry/customization/neurological-biomarkers-market/8040

Companies may utilize Neurological Biomarkers market report to get insights on market variables and any restraints that may affect the manufacturing of their product. Companies that are expanding abroad require thorough Global market research that includes real market data to assist with their marketing strategy. This Global market Neurological Biomarkers industry study analyzes important market dynamics and provides in-depth information and statistics to help companies flourish. This research report on the Neurological Biomarkers market takes advantage of advanced and professional approaches such as SWOT analysis and GRG Health’s unique GrowthMIX strategy.

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Neurological Biomarkers Market TOC: https://www.growthplusreports.com/report/toc/neurological-biomarkers-market/8040

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

QUICK BUY: https://www.growthplusreports.com/checkout-8040

Browse Latest Healthcare Reports:

Cannabis Drugs Market

Sterilization Wrap Market

Foley Catheters Market

Thrombin Market

Trauma Implants Market

Urinary Drainage Bags Market

Genetic Disease Diagnostics Market

Veterinary Diagnostics Market

Intraoral Scanners Market

Immunodiagnostics Market

Neurodegenerative Disease Drugs Market

Pet Insurance Market

Contact Us:

Manan Sethi Director, Market Insights Email: sales@growthplusreports.com Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

About Us Growth Plus Reports is part of GRG Health, a Global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.”

[healthcareinputs]

Neurodegenerative Disease Market Business Growth Analysis with Top Key Players -2026

Neurodegenerative diseases are incurable and debilitating conditions that result in progressive degeneration and/or death of nerve cells. This causes problems with movement (Ataxia), or mental functioning (dementia). The overall Global Neurodegenerative Disease Market is expected to grow at a significant compound CAGR rate of 6.8% from USD 32.65 billion in 2018 to USD 55.26 billion in 2026. This expansion in neurodegenerative disease is due to the ascending public awareness and robust product pipeline for neurodegenerative disease treatment. However, strict regulatory guidelines are restricting market growth. Moreover, increasing occurrence of neurological disorders is providing ample of opportunities.

Global Neurodegenerative Disease: Key Segments

By Indications: - Amongst indications, Alzheimer’s disease segment captured the largest market share of the global market due to Alzheimer's disease (AD) is the most widely neurodegenerative disease. This cause of dementia representing generally 50% everything being equal and in the old and is portrayed by the continuous loss of cognitive functions. Hallmark pathohistological findings of AD include widespread neuronal degeneration, extracellular amyloid plaques and intracellular neurofibrillary tangles (NFT) different lines of evidence indicate that AD grows primarily as the result of an amyloid cascade.

By Drug class: - Amongst Drug class, SSRIs segment captured the largest market share of the global market due to Sertraline (Zoloft) is a particular serotonin reuptake inhibitor (SSRI) that is generally prescribed as an antidepressant and proposed as a potential first-line medication to treat individuals with major depression. SSRIs work by improving the capacity of nerve cells in the brain that regulate emotion. Information is communicated between your brain cells with signals. The chemical messengers that deliver these signals are called neurotransmitters. Such as, sertraline was recently informed to inhibit several types of Na+ and K+ channels

By Region: - Neurodegenerative Disease market covers North America, Europe, Asia Pacific and the Rest of the world. North America region dominated the Neurodegenerative Disease market owing to the development of medical infrastructure and half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities and technological advancement. This region is significant for Parkinson's drugs market. As many as one million Americans live with Parkinson's disease (PD), which is joined the number of individuals people diagnosed to have numerous sclerosis, muscular dystrophy, and Lou Gehrig's disease. It is the second-most common neurodegenerative disorder in the United States. Additionally, there are a large number of patients who go undetected. As the US population keeps on maturing, the quantity of individuals living with Parkinson disease (PD) keeps on developing.

Request for sample pages @ https://www.optimainsights.org/sample-request/106-neurodegenerative-disease-market

Key Market Drivers: -

Global Neurodegenerative Disease Market Trends

·         Robust product pipeline for neurodegenerative disease treatment:

 The major driver for the growth of the Global Neurodegenerative Disease treatment market is a robust pipeline of drugs. For instance, FlorbetapirF 18 sponsored by Avid Radiopharmaceuticals has completed phase 2 clinical trials in 2017. This drug is used as biomarkers for neurodegenerative diseases such as Alzheimer’s disease. F 18 T807 sponsored by Washington school of medicine is in phase 2 clinical trials since 2015. This drug is used to treat Amyotrophic Lateral Sclerosis (ALS).

Global Neurodegenerative Disease Market: Restraints

·         The high Failure rate of Neurodegenerative drugs in clinical trials:

 Thus, there is a need for a greater and more detailed knowledge of the genetic basis and molecular pathology of neurodegenerative diseases. However, this must be matched by better clinical evaluation and understanding of the prodrome and evolution of these diseases and how to detect a meaningful change in clinical trials that can reflect successful modification of disease progression in a manner and timescale that is attractive to industry.

Global Neurodegenerative Disease Market: Opportunities and Challenges

·         Mergers and acquisitions by market players

 Mergers and acquisitions by market players are expected to provide ample opportunities for Neurodegenerative Disease market growth. For instance, in June 2018, Alexion Pharmaceuticals Inc. merged with Complement Pharma, Netherlands-based biotech company to develop preclinical C-6 complement inhibitor CP010 for neurodegenerative disorders such as Parkinson’s disease and Amyotrophic Lateral Sclerosis (ALS). C6 inhibition prevents the formation of Membrane attack complex (MAC), a complex of terminal complement proteins, which has the potential to treat a variety of central nervous system disorders.

·         Lack of reimbursement policies

 Lack of reimbursement policies provided by the government and hospitals for the treatment of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Amyotrophic Lateral Sclerosis (ALS) is restraining the growth of the market.

Neurodegenerative Disease Market Based on Drug class (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         Dopamine inhibitors

·         NMDA

·         SSRIs

 Neurodegenerative Disease Market Based on Indications (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         Huntington disease

·         Alzheimer’s disease

·         Parkinson’s disease

·         Amyotrophic Lateral Sclerosis

 Neurodegenerative Disease Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)

·         North America

·         Europe

·         APAC

·         LAMEA

 Neurodegenerative Disease Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)

·         Novartis International AG.

·         Pfizer Inc

·         Merck Serono

·         Biogen Idec

·         Teva Pharmaceutical Industries Ltd

·         UCB

·         Bayer Schering

·         Boehringer Ingelheim GmbH

·         Sanofi S.A.

·         GlaxoSmithKline Plc

·         Others

 Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/106-neurodegenerative-disease-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to take better business decisions towards attaining market leadership.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: chuksg@optimainsights.org

https://www.optimainsights.org

[tritonmarketresearch]

Alzheimer’s Therapeutics and Diagnostics Market: Expansion Prospects

According to estimates, nearly 5.8 million individuals in the United States were reported to have Alzheimer’s disease (AD) in 2020; and by 2050, this number is expected to surge to 13.8 million individuals. The rising prevalence of this disease across the globe emphasizes the pressing need to develop effective diagnostic methodologies and treatments.

Triton Market Research puts forth that the Global Alzheimer’s Disease Therapeutics and Diagnostics Market is likely to grow with a CAGR of 6.98% in the forecasting period from 2022 to 2028.

Alzheimer’s is a neurodegenerative disease that attacks the neurons, gradually damaging a person’s memory, thinking skills, and ability to perform the simplest daily tasks. People in the age group of 65 years or older are more prone to this condition, as a result of aging. Thus, the rising elderly populace is a key factor driving the demand for AD therapeutics and diagnostics.

Key Diagnostic Methodologies

Computed Tomography leads the Diagnostics segment with a $339.50 million revenue in 2021.

The mortality rate from Alzheimer’s can be minimized if the disease is diagnosed and treated in the early stages. Computed Tomography (CT) is an advanced and cost-effective diagnostic procedure for AD.

As per Medscape, the cost of a CT scan is nearly 20% less than that of an MRI scan

. The benefits offered by this technique and its effectiveness in diagnosing AD are driving the overall segment’s growth.

Blood Test is estimated to grow with the fastest CAGR in the Diagnostics segment, with a 20.93% CAGR during 2022-2028.

Blood testing for AD is an emerging technique that could help detect the disease prior to its onset or in those showing early symptoms. Several players are engaged in developing blood-based tests to identify Alzheimer’s disease biomarkers, as this approach is less invasive and more affordable than the currently available brain imaging and spinal fluid tests. Most of these pipelined products are awaiting marketing approval from the US Food and Drug Administration (FDA) and are most likely to be launched towards the end of the forecast period.

Stringent Regulations – Major Roadblock

According to Alzheimer’s Drug Discovery Foundation, the pharmacological treatment for AD is first tested during clinical trials registered with ClinicalTrials.gov, a registry of publicly & privately funded clinical studies under the National Institutes of Health (NIH). In the US, any company that intends to manufacture a new drug, has to seek approval from the FDA, prior to conducting clinical trials. Similarly, in Japan, companies are required to seek approval from the regulatory body

Pharmaceutical and Medical Devices Agency (PMDA).

The process is extremely cumbersome, as the manufacturers have to submit multiple applications for review before every phase of the trial. Also, post the successful completion of these trials, they must apply for licenses to market the drug. Such stringent regulations for drug development and commercialization are hampering the market’s growth.

Growing Number of Pipeline Drugs – Opportunistic Trend for Therapy

There are several drugs in the pipeline for AD, aimed at cognitive enhancement or neuropsychiatric symptoms control. There are also certain pipeline drugs aimed at preventing, delaying, or slowing the progression of Alzheimer’s. The Alzheimer’s Association estimates that the disease’s prevalence can be reduced by 50% if its onset is delayed by five years. The association further states that, currently, there are 143 drugs in the pipeline for its treatment. In July 2021, Eli Lilly and Company collaborated with Banner Alzheimer’s Institute on the Phase 3 prevention trial for donanemab.

Future Outlook

There is a high potential for developing a superior diagnosis for Alzheimer’s disease, compared to the diagnostic tests available at present. A research article published in Frontiers in Neurology (2020) states that newer techniques, which include the incorporation of PET neuroimaging and other genomics & proteomics biomarkers, are being adopted into revised diagnostic criteria.

Further, significant side effects of medicines and an unexpected lowered patient response towards treatment can be potential application areas for personalized therapy. It allows for a more accurate diagnosis and more effective treatment, with its patient-specific approach. Thus, the emergence of new diagnostic technologies and the development of personalized medicine indicate an overall positive outlook for the Alzheimer’s disease therapeutics and diagnostics market.

[mrfrblogresearch02]

Biomarkers Market Strategy, Outlook and Product Development and COVID-19 Impact Analysis 2027

Market Overview: Biomarkers are defined as biological measures of a biological state. It is an indicator of normal biological processes, pharmacological responses or pathogenic processes for therapeutic intervention.

The global biomarkers market Size, during the forecast period 2019 to 2027, will register growth at a CAGR of 10.28%. The market for biomarkers is set to reach US$4,582.8 million income by 2027.

Biomarkers are clinical measures for assessment such as blood pressure or cholesterol level and help in monitoring and predicting health status in individuals as well as in populations which promotes planning of appropriate therapeutic intervention. Biomarkers are used to predict serious illnesses such as diabetes and cardiovascular disease. Each individual biomarker indicates whether there is a disease or health state and can be combined to provide a detailed picture of how healthy a person is and whether or not a diagnosis needs to be made. Biomarkers have proved to be especially helpful in cancer research as certain DNA or RNA markers may therefore help in the detection and treatment of specific cancers.

Market Segmentation: The biomarkers market size has been segmented into disease indication, application, type, and product. Based on the segment, which is disease indications, the market is categorized on the basis of cancer, cardiovascular disorders, immunological disorders, neurological disorders, and others. The global market for biomarkers is further segmented based on application into diagnostics, disease risk assessment, drug discovery and development, and personalized medicine. Furthermore, the market, on the basis of type, is segmented into efficacy biomarkers, safety biomarkers, and validation biomarkers. Based on the segment, which is product, the market is categorized on the basis of consumables, services, and software. The global market research report covers all the aspects of the market based on the segmental analysis of these disease indications, application, type, and product segments. Analysts have also studied the global market's regional markets spread across many continents and countries. The disease indication, application, type, and product segments along with their sub-segments have been analyzed and companies functioning in the market across these segments are profiled and analyzed based on input and feedback from market-based decision makers as well as primary and secondary sources. The biomarkers market research report presents analysis-based information for companies functioning in the market.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1941 Regional Overview:

The spike in cancer cases globally may hinder the market growth. The market research report suggests that companies in the market could be supported by the spike in cancer cases globally as well as increasing applications and advancements of biomarkers during the forecast period. The market is set to register growth at a high CAGR owing to these key factors. The biomarkers market is spread across North America, Europe, Asia-Pacific, and other parts of the world. The global market research report reveals that APAC, North America, and Europe regional markets will dominate the global market for biomarkers during the forecast period 2019 to 2027. As per market analysts, the market is set to witness tremendous growth across consumables and safety biomarkers segments in North America which covers markets across the United States, Canada, Mexico and several other regional markets. Companies active in the market are also analyzed and studied in the market research report. The market for Europe covers smaller market segments of Germany, Italy, France, and the United Kingdom. Additionally, the market research report covers the Asia-Pacific region covering markets from India, China, Japan, Australia, and others. The biomarkers market is also spread across the rest of the world. The market report covers all such regions including the Middle East, Africa, Brazil, and others.

Competitive Landscape:

Qiagen N.V.,

Thermo Fisher Scientific Inc.,

Hoffmann-La Roche Ltd,

PerkinElmer Inc.,

Merck KGaA,

Bio-Rad Laboratories,

Abbott Laboratories,

EKF Diagnostics,

Enzo Biochem Inc.,

Meso Scale Diagnostics, LLC,

Signosis

PerkinElmer Inc.

Industry News: Medidata, a life science technology and clinical trial data firm, reported today that it has acquired the automated biomarker business of sensor manufacturer MC10. The deal's terms were kept under wraps. The acquisition would enable Medidata (a subsidiary of Dassault Systems) to incorporate biometric data and new analytics tools to its Patient Cloud platform, which will support patient-reported results, clinical outcome evaluations, and novel biomarker discovery, according to the company. Meanwhile, large corporations such as Johnson & Johnson and LabCorp have made significant efforts within their divisions to make remote clinical trial designs more feasible.

Browse Detailed TOC with COVID-19 Impact Analysis at:

https://www.marketresearchfuture.com/reports/biomarker-market-1941

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com

[virtualcollectiveparadise]

Global Neuroendocrine Tumor Treatment Market: Industry Analysis and Forecast (2020-2026)

Global Neuroendocrine Tumor Treatment Market is expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 11% during forecast period.

Global Neuroendocrine Tumor Treatment Market Overview:

The improper growth of neoplasms that arise from cells of the numerous endocrine glands and neurological systems causes neuroendocrine tumours. These are commonly called carcinoid tumours because they get infected first in the intestine. Global Neuroendocrine Tumor Treatment Market Dynamics:

Increasing prevalence of Neuroendocrine Tumor is expected to propel the market growth.

Increased incidences of neuroendocrine tumours (NETs) are predicted to boost demand for treatment options, boosting the market growth during the forecast period. Novel therapeutics and diagnostic products are being developed at a rapid pace in this field. Neurofibromatosis type 1 (NF1), Multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), Von Hippel- tuberous sclerosis complex (TSC) and Lindau syndrome (VHL) disease are all increasing the incidence and prevalence of neuroendocrine tumours (NETs) in the United States. Furthermore, according to a study published in the JAMA Oncology Journal in 2017, the survival rate of all neuroendocrine tumour treatments have improved, particularly in the treatment of distant-stage gastrointestinal neuroendocrine tumours and pancreatic neuroendocrine tumours. This is mostly due to the availability of effective medicines and early disease detection.

The market for neuroendocrine tumour treatment is predicted to grow due to the development of new medications. Cancer can be treated in a variety of ways. One of the most popular treatment options for neuroendocrine tumours is targeted therapy. Cancer treatment that uses targeted therapy is quite effective. As a result, targeted NET therapies are predicted to become more popular in the forecast years. Over the forecast period, the market is expected to grow due to an increase in the number of pharmacological approvals for the treatment of neuroendocrine tumours. For example, in January 2018, Novartis Groupe S.A.'s Advanced Accelerator Applications received FDA approval of its new drug application (NDA) for Lutathera for the treatment of Somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), which include foregut, midgut, and hindgut neuroendocrine tumours.

The report has profiled eighteen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region. Global Neuroendocrine Tumor Treatment Market Segment Analysis:

The Global Neuroendocrine Tumor Treatment Market is segmented on the basis of Product, Indication and End-users.

Based on Product, the Somatostanin Analogs segment is expected to dominate the global market during the forecast period. Somatostanin Analogs (SSAs) are the most commonly utilized medications to treat neuroendocrine carcinoma because they reduce cancer growth, symptoms, and target biomarkers. Because of the safe treatment procedures provided by SSAs, they account for the biggest revenue share. SSAs are commonly utilized to treat patients who have failed to respond to radiation therapy or surgery. As a result, many SSAs are now in clinical trials and awaiting clearance, and the market is likely to grow rapidly over the forecast period. Tarveda Therapeutics' PEN-221 and Dauntless Pharmaceuticals' DP1038 are two examples. Drugs like Sunitinib and Everolimus are used in targeted therapy. These medications are used as the first line of therapy for neuroendocrine carcinoma since they have less negative effects. Chemotherapy, radiation therapy, surgery, and tyrosine kinase inhibitors are among the additional products available.

Global Neuroendocrine Tumor Treatment Market

To know about the Research Methodology :- Request Free Sample Report

Based on Indication, the gastrointestinal segment accounted for the dominant segment in 2019 as NETs are more likely to arise in the GI tract. According to data provided in a Novartis investor presentation in 2015, GI tumours account for 61% of all NETs, with the small intestine tumour being the most common. According to the American Society of Clinical Oncology (ASCO), roughly 8,000 persons in the United States have diagnosed with GI tract-carcinid tumours in 2016. Over the projected period, the rising occurrence of carcinoid tumours in the GI tract is expected to propel the segment forward. Global Neuroendocrine Tumor Treatment Market Regional Insights:

Global Neuroendocrine Tumor Treatment Market Regional Insights

North America is expected to dominate the global market throughout the forecast period.

Because of the increased frequency of neuroendocrine illnesses, developed health care infrastructure, strong clinical pipeline, high level of awareness among individuals, and presence of significant market participants, North America dominates the neuroendocrine tumours market. In this area, there are also supporting insurance programmes, such as Medicare, Medicaid, and Tricare, which make neuroendocrine treatment grow during forecast years. For example, Ipsen got FDA clearance for its Somatuline Depot (lanreotide) Injection 120 mg in December 2014, which is approved for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally progressed or metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

In addition, the European neuroendocrine tumour therapy market is predicted to grow significantly over the forecast period, owing to an increase in product approvals by the European Commission (EC) for marketing in European countries.

The report also helps in understanding Global Neuroendocrine Tumor Treatment Market dynamics, structure by analyzing the market segments and project the Global Neuroendocrine Tumor Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Neuroendocrine Tumor Treatment Market make the report investor’s guide.

For More Info : https://www.maximizemarketresearch.com/market-report/global-neuroendocrine-tumor-treatment-market/110060/

Global Neuroendocrine Tumor Treatment Market Scope: Inquire before buying

Global Neuroendocrine Tumor Treatment Market Global Neuroendocrine Tumor Treatment Market, by Region:

• North America • Europe • South America • MEA • APAC Global Neuroendocrine Tumor Treatment Market, Key players:

• Novartis AG • Boehringer Ingelheim International GmbH • Pfizer, Inc. • Ipsen Pharma • AVEO Oncology • Hutchison MediPharma Limited • Progenics Pharmaceuticals • F. Hoffmann-La Roche Ltd • Bristol-Myers Squibb Company • Viatris Inc. • Thermo Fisher Scientific Inc. • Regeneron Pharmaceuticals, Inc. • Sun Pharmaceutical Industries Ltd. • Teva Pharmaceutical Industries Ltd. • Eli Lilly and Company • LUPIN • Advanced Accelerator Applications • BioSynthema Inc. For More Information Visit @:Maximize Market Research Company This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

[market-research-future]

biomarker technologies Market Share, Dynamics, Outlook And Segmentation | Forecast to 2027

Market Highlights

The biomarker technologies market is expected to reach USD 78 Billion by 2023 at a CAGR of 9% during the forecast period. The term biomarker is usually used to define a measurable indicator of some biological state or condition. It is also referred to a substance whose detection indicates the presence of a living organism. Biomarkers are used for diagnosis and clinical decision making in cancer, diabetes, and cardiovascular and neurological diseases. The market for biomarker technologies is growing worldwide due to drivers such as increased occurrence of above diseases, advances in the area of medical technologies, governmental initiatives supporting research in the area of biomarker technologies, and increasing uses of biomarkers to increase the accuracy of disease diagnosis. However, high capital investments required for the discovery, development of biomarkers, and the high cost of biomarkers are restraining the growth of the biomarker technologies market.

Regional Analysis

Americas has the largest market share in the biomarker technologies market. The increasing prevalence of cancer, cardiovascular diseases, neurological as well as autoimmune diseases, and rising geriatric population are likely to enhance the growth of the biomarker technologies market.  For instance, the National Cancer Institute (NCI) had stated that 1,666,540 new cases of cancer were reported during 2014 in the United States. Thus, this increasing patient pool will enhance the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research and development in advanced medical treatment options, and availability of favorable reimbursement policies are likely to propel the growth of the biomarker technologies market in the American region. Furthermore, according to CMS (Centers for Medicare and Medicaid Services) the U.S. health care spending increased by 4.3 percent to reach USD 3.3 trillion per person in 2016. Thus, increasing per capita income of individuals as well as rising healthcare spending will aid up the market growth in Americas.

Access Report @ https://www.marketresearchfuture.com/reports/biomarker-technologies-market-6150

Europe is the second largest market leader and holds a healthy share in the global biomarker technologies market. The European market is expected to exhibit a sturdy growth rate during the forecast period owing to the availability of advanced treatment facilities and established healthcare infrastructure, along with the growing need for efficient and accurate diagnosis. Furthermore, according to the Cancer Research U.K., there were around 9, 921 cases of cancer diagnosed in 2015. The increasing occurrence of cancer is expected to have a positive impact on the biomarker technologies market due to its wide usage in cancer. This impact will enhance the biomarker technologies market in Europe.

Asia Pacific is expected to be the fastest emerging market. Factors such as the increasing prevalence of chronic diseases are the major driver for the market growth. For instance, in accordance with the International Diabetes Federation, nearly 382 million people had diabetes in 2013 worldwide. This is expected to reach around 500 million by the end of 2035. China and India are the first and second most affected countries with diabetes. This rising number of diabetic patients can lead to the increasing patient number with cardiovascular diseases. So, these countries are expected to be the fastest growing regions due to the increasing patient pool, raising awareness about health, and availability of new treatment methods.

The Middle East and Africa is expected to witness a limited growth due to limited access to healthcare resources and rising healthcare cost. In the Middle East, the growth of the market is driven by Saudi Arabia and the United Arab Emirates due to increasing research and development for newer technologies and rising healthcare infrastructure.

Segmentation

The global biomarker technologies market is segmented on the basis of product type, profiling technology, disease application, and research areas. Considering product type, the market is segmented into consumables, instruments, services, and software/informatics.

By profiling technology, the market is segmented into immunoassay, PCR, imaging technology, mass spectrometry, NGS, chromatography, cytogenetics, and other technologies. Based on immunoassay, the market is again segmented into ELISA, western blot, and protein microarray.

With reference to disease application, the market is segmented into cancer, infectious disease, autoimmune diseases, neurological, cardiovascular disorders, and other disorders.

On account of research areas, the market is segmented into Genomics, Proteomics, Metabolomics, and other research areas. Metabolomics is further segmented into lipidomic and others.

Based on region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.

Key Players

Market Research Future (MRFR) recognizes the following companies as the key players in the biomarker technologies market. Some of the players are Abbott Laboratories, Agilent Technologies (U.S.), Thermo Fisher Scientific (U.S.), Roche (Switzerland), Waters Corporation (U.S.), Danaher Corporation (U.S.), Shimadzu Corporation (Japan), Siemens Healthcare, and Bio-Rad Laboratories (U.S.).    

Browse Related Reports at:

Blood Collection Market Research Report - Forecast to 2027 | MRFR

Irritable Bowel Syndrome Treatment Market Analysis, Growth Values and Forecast to 2027

Oxygen Therapy Equipment Market by Product, Portability, Applications and Global Forecast to 2027

[decisionforsight]

Asia Pacific Radiopharmaceutical Market

Asia Pacific Radiopharmaceutical Market Size, Share, Growth, Industry Trends and Forecast 2020-2030

Radiopharmaceuticals are a group of pharmaceutical drugs that contains radioactive isotopes. They are also used as therapeutic and diagnostic agents. Radiopharmaceuticals are used for molecular imaging, involving in the use of these molecules as biomarkers for precise molecular processes that control the progress of a disease. The Asian radiopharmaceutical market is expected to grow rapidly due to increasing awareness among individuals and rising diagnostic rates. This will fuel the demand for SPECT and PET devices in this market. Another factor for its growth is the rise in the number of healthcare facilities and improvement in hospitality. Since most of the countries in this region are developing nations, and working towards the establishment of a stable and efficient healthcare system, it will be an excellent opportunity for the sale of radiopharmaceutical products. APAC Radiopharmaceuticals market was valued at USD 2 billion in 2020 and is expected to be valued at USD 5.6 billion by 2030, witnessing an approximate CAGR of 10.9% over the forecast period.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures) @ https://www.decisionforesight.com/request-sample/DFS020159

Market Dynamics and Factors:

Radiopharmaceutical diagnostic techniques offer a better insight into the disease than the conventionally used diagnostic devices, including x-ray, CT, ultrasound, and MRI. Since these diagnostic techniques are new to the developing countries, the scope for the growth is more. On the other hand, strict regulation of the radioactive elements, complex manufacturing processes, and comparatively high prices of the devices are the major restraints. High efficiency, ability to mix with other diagnostic techniques such as x-ray and growing awareness of this technique in the developing market are the major factors expected to fuel the growth of the diagnostic radiopharmaceuticals during the forecast period.

Market Segmentation : 

Asia Pacific Radiopharmaceutical Market – By Source

Nuclear Reactors

Cyclotrons

Asia Pacific Radiopharmaceutical Market – By Radioisotope

Technetium-99

Gallium-67

Iodine-123

Iodine-125

18F

Rubidium-82

Yttrium-90

Lutetium-177

Others

Asia Pacific Radiopharmaceutical Market – By Application

Gastro-intestinal

Oncology

Brachytherapy

Others

Nephrology

Cardiology

Neurology

Inflammation

Others

Asia Pacific Radiopharmaceutical Market – By Type

PET/CT

SPECT

Therapeutics

Asia Pacific Radiopharmaceutical Market – By End-User

Hospitals

Ambulatory Surgical Centers

Diagnostic Centers

Cancer Research Institutes

Others

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC at @ https://www.decisionforesight.com/toc-request/DFS020159

Geographic Analysis:

Japan, China, India, Australia, and South Korea, holds major shares of the market in the Asia Pacific due to the production of radioisotopes, out of which Japan is the major producer of the same. The market in Japan is expected to be prominent during the forecast period due to the activities of Sumitomo Corporation, which supplies radioactive raw material to radiopharmaceutical companies. After the introduction of a new accelerator system for the production of radioisotopes in Japan and Australia the radiopharmaceutical market is expected to grow at a higher pace. Some of the factors likely to boost the radiopharmaceutical market in the Asia Pacific are increasing in access to healthcare services, growth in per capita income, rise in demand for radiopharmaceuticals, the surge in the incidence of cancer and heart-related diseases, and speedy introduction of advanced technological systems such as PET/CT, SPECT.

Competitive Scenario:

The major players of the operating in the market are GE Healthcare, Lantheus Medical Imaging, Inc., Mallinckrodt, Siemens Healthiness, Advanced Accelerator Applications, Bayer AG, Eckert & Ziegler, IBA Radiopharma Solutions, Philips, and Jubilant Life Sciences Limited.

Connect to Analyst @ https://www.decisionforesight.com/speak-analyst/DFS020159

How will this Market Intelligence Report Benefit You?

The report offers statistical data in terms of value (US$) as well as Volume (units) till 2030.

Exclusive insight into the key trends affecting the Asia Pacific Radiopharmaceutical industry, although key threats, opportunities and disruptive technologies that could shape the Asia Pacific Radiopharmaceutical Market supply and demand.

The report tracks the leading market players that will shape and impact the Asia Pacific Radiopharmaceutical Market most.

The data analysis present in the Asia Pacific Radiopharmaceutical Market report is based on the combination of both primary and secondary resources.

The report helps you to understand the real effects of key market drivers or retainers on Asia Pacific Radiopharmaceutical Market business.

The 2021 Annual Asia Pacific Radiopharmaceutical Market offers:

100+ charts exploring and analysing the Asia Pacific Radiopharmaceutical Market from critical angles including retail forecasts, consumer demand, production and more

15+ profiles of top producing states, with highlights of market conditions and retail trends

Regulatory outlook, best practices, and future considerations for manufacturers and industry players seeking to meet consumer demand

Benchmark wholesale prices, market position, plus prices for raw materials involved in Asia Pacific Radiopharmaceutical Market type

Buy This Premium Research Report@ https://www.decisionforesight.com/checkout/DFS020159

About Us:

Decision Foresight is a market research organization known for its reliable and genuine content, market estimation and the best analysis which is designed to deliver state-of-the-art quality syndicate reports to our customers. Apart from syndicate reports, you will find the best market insights, strategies that will help in taking better business decisions on subjects that may require you to develop and grow your business-like health, science, technology and many more. At Decision Foresight, we truly believe in disseminating the right piece of knowledge to a large section of the audience and cover the in-depth insights of market leaders across various verticals and horizontals.

Contact:

Email: sales@decisionforesight.com

For Latest Update Follow Us:

https://www.facebook.com/Decision-Foresight-110793387201935

https://twitter.com/DecisionFs

https://www.linkedin.com/company/decision-foresight/

[techsciresearch]

Precision Medicine Market to Witness 10.65% CAGR until 2026 | TechSci Research

Increasing advancements in cancer biology and myriad benefits offered by precision medicines to drive the global precision medicine market.

According to TechSci Research report, “Global Precision Medicine Market By Products and Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, Next Generation Sequencing (NGS), Others), By Application (Oncology, Immunology, Cardiology, Neurology, Respiratory, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition Forecast & Opportunities, 2026”, the global precision medicine market was valued at USD66.85 billion in 2020 and is expected to reach USD125.67 billion by registering a CAGR of 10.65% during the forecast period due to shift towards precision medicine, increase in genetic diseases and development of technologies such as next generation sequencing.

Unlike general medicines that are disease-specific and fit for all, the precision medicines focus on the individual diseases. They are patient-based medicines which help the doctors to give optimized treatment to the patients, thereby driving the precision medicine market across the globe. Additionally, international projects such as the Human Genome Project (HGP), funded by the United States government via National Institutes of Health (NIH) are based on precision medicines and provide a deeper understanding of the same. Even though the precision medicines come with an ample number of advantages, they are costly, which might hinder the growth of the market across the globe.

Browse 138 Figures spread through 110 Pages and an in-depth TOC on "Global Precision Medicine Market"

https://www.techsciresearch.com/report/precision-medicine-market/4684.html

The global precision medicine market is segmented based on products and services, technology, application, end user, and region. The application segment is further divided into oncology, immunology, cardiology, neurology, respiratory and others. Out of these, oncology held the largest market share in 2020 due to the increasing cases of cancer all over the world.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4684

Customers can also request for 10% free customization on this report.

Some of the leading players in global precision medicine market include IBM Watson Group, Roche Holding AG, Thermo Fischer Scientific Inc., Philips Healthcare Ltd., Illumina Inc., Quest Diagnostics Inc., Qiagen NV, AstraZeneca Plc, Agilent Technologies Inc., Novartis AG, NanoString Technologies Inc., NantHealth Inc., Orion Health Inc., Celcuity Inc., InsightRX, Inc., and others. In order to sustain the strong competition, companies adopt various strategies like new product launches, collaborations and many more to provide the best precision medicines to the patients. For instance, Novartis has acquired CellforCure, which has expanded its manufacturing capacity for innovative cell and gene therapies.

In June 2020, Thermo Fisher Scientific Inc., the world leader in serving science announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC's mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation and create new opportunities for precision medicine.

“In terms of regional analysis, North America dominated the global precision medicine market until 2020, due to favorable government initiatives, heavy investments by the United States in medical research like Human Genome Project (HGP) and growing cases of respiratory and oncology diseases. However, Asia-Pacific region is expected to grow at the highest CAGR through 2026 because of the increasing prevalence of genetic and cancer diseases in countries like China and India” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Precision Medicine Market By Products and Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, Next Generation Sequencing (NGS), Others), By Application (Oncology, Immunology, Cardiology, Neurology, Respiratory, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition, Forecast & Opportunities, 2026” has evaluated the future growth potential of global precision medicine market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global precision medicine market.

Browse Related Reports:

Global Bioinformatics Market By Product & Services (Bioinformatics Tools, Bioinformatic Platforms and Bioinformatic Services), By Type (Genomics & Proteomics, Simulation Studies & Molecular Modelling, Genetic Engineering, Others), By Application (Metagenomics, Drug Discovery, Precision Medicine, Others), By End User (Institutional Research v/s Industrial Research), By Region, Competition, Forecast & Opportunities, 2016-2026F

https://www.techsciresearch.com/report/bioinformatics-market/4279.html

Global Medical Electronics Market By Product Type (Therapeutic and Diagnostics), By End-user (Hospital, Ambulatory Surgical Center, Clinic & Others), By Region (North America, Europe, Asia-Pacific & Others), Competition, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/medical-electronics-market/3896.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[poonamcmi]

Neurodiagnostics Market Estimated to Witness High Growth Owing to Growing Geriatric Population

The neurodiagnostics market plays a crucial role in neurological disease diagnosis and treatment monitoring. Neurological disorders such as epilepsy, Alzheimer's disease, Multiple Sclerosis, Parkinson's disease, and other neurological conditions are becoming increasingly prevalent. Neurodiagnostics help detect neurological abnormalities through neurological imaging such as MRI, EEG, and diagnostic tests. The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics.

The Global Neurodiagnostics Market is estimated to be valued at US$ 8.66 Bn in 2024 and is expected to exhibit a CAGR of 8.1% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the neurodiagnostics are Koninklijke Philips N.V, Siemens Healthcare GmbH, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, Bio-Rad Laboratories Inc., Advanced Brain Monitoring, Inc., Nihon Kohden Corporation, Mitsar Co. LTD., EMS Biomedical, Mennen Medical, Natus Medical Incorporated, Medicaid Systems, Fujirebio, FONAR Corp, ANT Neuro, NEUROLITE AG, and Atlantic Health System.

The key opportunities in the Neurodiagnostics Market Demand include increasing investments in R&D for biomarker-based disease diagnosis and neuroimaging. The global expansion of key players through mergers and acquisitions will further aid market growth.

The growing geriatric population is more susceptible to neurodegenerative diseases, driving the need for neurodiagnostics. Furthermore, increasing investments in R&D by key players for developing advanced diagnostic systems will boost the neurodiagnostics market over the forecast period.

Market drivers

The growing geriatric population is the major driver propelling the Neurodiagnostics Market Size And Trends As per the United Nations, people aged over 60 years are projected to outnumber children under 10 years by 2050. Elderly people are more vulnerable to neurological disorders like Alzheimer's and Parkinson's disease. This will augment the demand for neurodiagnostics for early disease diagnosis and treatment monitoring. Increasing awareness about brain health and availability of reimbursement policies for neurodiagnostic tests will also boost market revenues significantly over the forecast period.

PEST Analysis

Political: Regulations related to medical devices and neurological disorder treatments have an impact. Reimbursement policies by governments and insurance agencies also affect market growth. Economic: The growing insurance coverage levels and disposable incomes have boosted healthcare spending including on neurodiagnostics. Higher investments in clinical trials and R&D remain crucial. Social: Rising prevalence of neurological disorders like Alzheimers, Parkinsons, epilepsy, and stroke is a key driver. Growing awareness encourages early diagnosis through imaging techniques. Technological: Advancements in imaging modalities like MRI, CT, PET, EEG, and newer technologies like digital EEG and MEG expands diagnosis capabilities. Portable and wearable devices improve accessibility.

Geographical Regions with High Market Concentration North America accounts for the largest share in the neurodiagnostics market in terms of value, owing to the presence of major players, high healthcare expenditure, and rising neurological disorders. The United States holds a significant share in the regional market.

Fastest Growing Regional Market

The Asia Pacific region is expected to witness the highest growth in the neurodiagnostics market during the forecast period. This is attributed to factors such as growing healthcare expenditure, increasing healthcare infrastructure development, and rising geriatric population in the region suffering from neurological conditions. Rapidly developing countries like China and India with huge patient pools offer high growth potential. Get More Insights On, Neurodiagnostics Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[techscimarketresearch]

Precision Medicine Market to Witness 10.65% CAGR until 2026 | TechSci Research

Increasing advancements in cancer biology and myriad benefits offered by precision medicines to drive the global precision medicine market.

According to TechSci Research report, “Global Precision Medicine Market By Products and Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, Next Generation Sequencing (NGS), Others), By Application (Oncology, Immunology, Cardiology, Neurology, Respiratory, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition Forecast & Opportunities, 2026”, the global precision medicine market was valued at USD66.85 billion in 2020 and is expected to reach USD125.67 billion by registering a CAGR of 10.65% during the forecast period due to shift towards precision medicine, increase in genetic diseases and development of technologies such as next generation sequencing.

Unlike general medicines that are disease-specific and fit for all, the precision medicines focus on the individual diseases. They are patient-based medicines which help the doctors to give optimized treatment to the patients, thereby driving the precision medicine market across the globe. Additionally, international projects such as the Human Genome Project (HGP), funded by the United States government via National Institutes of Health (NIH) are based on precision medicines and provide a deeper understanding of the same. Even though the precision medicines come with an ample number of advantages, they are costly, which might hinder the growth of the market across the globe.

Browse 138 Figures spread through 110 Pages and an in-depth TOC on "Global Precision Medicine Market"

https://www.techsciresearch.com/report/precision-medicine-market/4684.html

The global precision medicine market is segmented based on products and services, technology, application, end user, and region. The application segment is further divided into oncology, immunology, cardiology, neurology, respiratory and others. Out of these, oncology held the largest market share in 2020 due to the increasing cases of cancer all over the world.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4684

Customers can also request for 10% free customization on this report.

Some of the leading players in global precision medicine market include IBM Watson Group, Roche Holding AG, Thermo Fischer Scientific Inc., Philips Healthcare Ltd., Illumina Inc., Quest Diagnostics Inc., Qiagen NV, AstraZeneca Plc, Agilent Technologies Inc., Novartis AG, NanoString Technologies Inc., NantHealth Inc., Orion Health Inc., Celcuity Inc., InsightRX, Inc., and others. In order to sustain the strong competition, companies adopt various strategies like new product launches, collaborations and many more to provide the best precision medicines to the patients. For instance, Novartis has acquired CellforCure, which has expanded its manufacturing capacity for innovative cell and gene therapies.

In June 2020, Thermo Fisher Scientific Inc., the world leader in serving science announced new collaborations of the Thermo Fisher Precision Medicine Science Center (PMSC) with AstraZeneca and the University of Nebraska Medical Center as part of its ongoing development of innovative solutions for unmet needs in clinical biomarker discovery. The new alliances strengthen the PMSC's mission of creating standardized workflows with pharma and academic partners to streamline the transition from biomarker research to clinical implementation and create new opportunities for precision medicine.

“In terms of regional analysis, North America dominated the global precision medicine market until 2020, due to favorable government initiatives, heavy investments by the United States in medical research like Human Genome Project (HGP) and growing cases of respiratory and oncology diseases. However, Asia-Pacific region is expected to grow at the highest CAGR through 2026 because of the increasing prevalence of genetic and cancer diseases in countries like China and India” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Precision Medicine Market By Products and Services (Precision Medicine Platforms, Precision Medicine Tools, Precision Medicine Services), By Technology (Big Data Analytics, Artificial Intelligence, Bioinformatics, Whole Genome Sequencing, Companion Diagnostics, Next Generation Sequencing (NGS), Others), By Application (Oncology, Immunology, Cardiology, Neurology, Respiratory, Others), By End User (Pharmaceutical and Biotechnology Companies, Healthcare IT, Diagnostic Companies, Clinical Research Organization, Research Institutes), By Region, Competition, Forecast & Opportunities, 2026” has evaluated the future growth potential of global precision medicine market and provided statistics & information on market size, shares, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global precision medicine market.

Browse Related Reports:

Global Bioinformatics Market By Product & Services (Bioinformatics Tools, Bioinformatic Platforms and Bioinformatic Services), By Type (Genomics & Proteomics, Simulation Studies & Molecular Modelling, Genetic Engineering, Others), By Application (Metagenomics, Drug Discovery, Precision Medicine, Others), By End User (Institutional Research v/s Industrial Research), By Region, Competition, Forecast & Opportunities, 2016-2026F

https://www.techsciresearch.com/report/bioinformatics-market/4279.html

Global Medical Electronics Market By Product Type (Therapeutic and Diagnostics), By End-user (Hospital, Ambulatory Surgical Center, Clinic & Others), By Region (North America, Europe, Asia-Pacific & Others), Competition, Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/medical-electronics-market/3896.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[merin20]

How Will The Functional Brain Imaging Systems Market Grow With Technological Advancements?

As per the latest research by PMR, the global functional brain imaging systems market is estimated to account for revenues worth US$ 7 Bn by the end of 2029. The functional brain imaging systems market report also projects a significant growth prospective with a projected average Y-o-Y growth rate of around 7% during the forecast period.

Constant research and development in diagnostic imagining, increased potential of functional brain imaging systems for various neurological disorders and disease applications, coupled with the sanctions of subsidy, and support of government organizations for the R&D of advanced functional brain imaging systems remain the significant factors propelling the growth of functional brain imaging systems market.

Growing Criticality of Effective Diagnostic Imaging

Increase in the incidence of life-threatening diseases and brain injuries has led to the increasing usage of diagnostic procedures. It is estimated that the direct and indirect costs of brain imaging and diagnosis will increase over a period of time. EEG, fMRI and fNRI are the current key advanced products in the brain imaging system market as they have shown reliable results in many diagnostic and therapeutic areas for intracranial hemorrhage, hypoxic-ischemic encephalopathy, and congenital malformation.

Get Going With Sample Of Functional Brain Imaging Systems Market Report! https://www.persistencemarketresearch.co/samples/23050  

To fastback the development of cost-effective and efficient medical devices, such as fNRI, fMRI and multi-channel EEG devices etc., various governments in developed and developing countries are facilitating funding for R&D activities in their regions. For instance, in 2018, six research teams were awarded by Brain Canada and Heath Canada for working to improve and change the quality of life of people living with brain disorders and improve healthcare outcomes.

The constantly evolving healthcare diagnostic sector and new measurers for neurological disease management are anticipated to offer new growth opportunities for the global functional brain imaging systems market. Moreover, the growing necessity of intensive care in traumatic brain injury and brain aneurysm is boosting the demand for functional brain imaging systems.

Increasing adoption of functional brain imaging systems for the prevention of brain hemorrhage at ambulatory care centers and hospitals under the guidance of licensed caregivers is also anticipated to boost the functional brain imaging systems market over the forecast period. The introduction of novel radioactive biomarkers, when used with properly tested functional brain imaging systems, is boosting the popularity of the latter among physicians, oncologists, and surgeons. Functional brain imaging systems also find wide acceptance among patients owing to a significant value proposition in the treatment of brain related disorders.

How About Re-Inventing The Methodical Wheel In The Functional Brain Imaging Systems Market? Switch Over To The “Methodology” Tab! https://www.persistencemarketresearch.co/methodology/23050  

Manufacturers Seeking Profits through Direct Sales

The manufacturers of functional brain imaging systems are gradually intensifying their focus on providing services and upgrading their facilities to escalate market penetration. In this scenario, dependence on direct sales channels is mounting in economies such as India and China. Visits by direct sales personnel result in opportunities for the training of staff for the proper utilization of functional brain imaging systems for patients. This creates higher efficiency and training protocol for caregivers, which, creates the probability of recurring purchases from end users, which will, in turn, boost the sales of functional brain imaging systems.

A large number of manufacturers of functional brain imaging systems are positioning their products for high-capacity applications in addition to diagnostic procedures and high-complexity operative procedures. Moreover, companies are marketing functional brain imaging systems through direct sales representatives, seminars, brochures, and case studies, to facilitate higher product penetration for different diagnostic applications.

Currently, most of the PET scanning procedures are performed using Fluorodeoxyglucose (FDG), due to its capability to capture higher tissue glucose metabolism. However, FDG also has several shortcomings, the most important one being its specificity. The radiotracer cannot be utilized in the diagnosis of several cancers such as prostate cancer, carcinoma, or brain tumors. Several potential radiotracers are currently under investigation to address the unmet clinical needs of disease diagnosis in the functional brain imaging system market. For instance, Piramal’s diagnostic imaging pipeline includes two radiotracers, 68Ga-RM2 and 68Ga-PSMA (both labelled with radioactive isotope 68 Gallium), for potential use in cancer diagnosis, especially prostate cancer.

Keeping A Tab On Key Players In The Functional Brain Imaging Systems Market? Go To “Purchase Now” To Decipher The Competitive Analysis In Our Functional Brain Imaging Systems Market Report! https://www.persistencemarketresearch.com/checkout/23050

PMR has segmented the global market for functional brain imaging systems based on modality, end user, region, and product type. By product type, the market for functional brain imaging systems is further segmented into Magnetoencephalography (MEG) System, Functional MR Imaging (fMRI), Positron Emission Tomography (PET) System, System, Functional near Infrared Spectroscopy (fNIRS) System, and Electroencephalography (EEG) System. On the basis of modality, the functional brain imaging systems market is further segmented into stand-alone device and portable device. On the basis of end user, the functional brain imaging systems market is segmented into office-based clinics, hospitals, diagnostic imaging centers, and ambulatory surgical centers

The report tracks some of the major companies operating in the functional brain imaging systems market, which include Koninklijke Philips N.V., General Electric Company, Canon Medical Systems Corporation, EB Neuro S.p.A., MinFound Medical Systems Co. Ltd, Neurosoft, Medtronic Plc., Nihon Kohden Corporation., Hitachi Medical Systems, Elekta, and Siemens AG.

Explore Extensive Coverage of Persistence Market Research’s Healthcare Industry

About us:      

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

Contact us:

Persistence Market Research Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States U.S. Ph. – +1-646-568-7751 USA-Canada Toll-free – +1 800-961-0353 Sales – sales@persistencemarketresearch.com